Salta ai contenuti. | Salta alla navigazione

Strumenti personali

sito non più aggiornato
 

Sezioni

Tu sei qui: Home / Docenti / Fabrizio FAGGIANO / Fabrizio FAGGIANO: Pubblicazioni

Fabrizio FAGGIANO: Pubblicazioni

ultima modifica 22/02/2012 14:17
  1. Rocca P, Calvarese P, Faggiano F, Marchiaro L, Mathis  F, Rivoira E, Tarocco B, Bogetto F. Citalopram versus sertraline in late-life non-major clinically significant depression: a one-year follow-up clinical trial. Journal of Clinical Psychiatry 2005; 66: 360-369 (IF 2007: 5.060) (1°quint)
  2. Bargagli AM, Davoli M, Schifano P, Faggiano F, Perucci CA and the Vedette study group Determinants of methadone treatment assignment among heroin addicts on first admission to public treatment centres in Italy. Drug and Alcohol Dependence 2005; 79: 191–199. (IF 2007: 3.222) (1°quint)
  3. Amato L, Davoli M, Perucci CA, Ferri M, Faggiano F, Mattick RP. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J Subst Abuse Treat. 2005; 28:321-9
  4. Faggiano F, Vigna-Taglianti FD, Versino E, Zambon A, Borraccino A, Lemma P. School-based prevention for illicit drugs' use. Cochrane Database of Systematic Reviews 2005; issue 2:CD003020 . (IF 2007 4.654) (1°quint)
  5. Diecidue R, Iannaccone A, Lampis F, Mathis F, Davoli M, Bargagli AM, Faggiano F. Studio VEdeTTE - Monografia 3: Studio Pilota VEdeTTE 2. Torino 2005
  6. Mathis F, Bargagli AM, Scarmozzino A, Davoli M, Versino E, Piras G, Faggiano F, Pani PP, Martini C, Cauda V. Studio VEdeTTE - Monografia 2: Studio Pilota VEdeTTE 1. Torino, 2005
  7. Versino E, Bargagli AM, Salamina G, Amato L, Mathis F, Piras G, Cuomo L, Schifano P, Faggiano F, Davoli M. Monografia n. 4 - Analisi descrittiva della coorte arruolata nei primi 18 mesi dello studio. Torino 2005
  8. Vigna-Taglianti F, Bargagli AM, Mathis F, Schifano P, Decidue R, Amato L, Salamina G, Piras G, Cuomo L, Davoli M, Faggiano F, Belleudi V. Monografia n. 5 - Analisi dei trattamenti dei primi 18 mesi dello studio. Torino 2005
  9. Vigna-Taglianti F, Vineis P, Liberati A, Faggiano F. Quality of systematic reviews used in guidelines for oncology practice. Annals of Oncology 2006; 17: 691-701 (IF 2007: 4.875) (1°quint)
  10. Schifano P, Bargagli AM, Belleudi V, Amato L, Davoli M, Diecidue R, Versino E, Vigna-Taglianti F, Faggiano F, Perucci CA. Methadone treatment in clinical practice in Italy: need for improvement. Eur Addict Res 2006;12(3):121-7.
  11. Oggé G, Gaglioti P, Maccanti S, Faggiano F, Todros T and the Gruppo Piemontese for Prenatal Screening of Congenital Heart Disease. Prenatal screening for congenital heart disease with four-chamber and outflow-tract views: a multicenter study. Ultrasound Obstet Gynecol 2006; 28: 779–784 (IF 2007 2.672) (1°quint)
  12. Faggiano F, Vigna-Taglianti F. Systematic reviews of effectiveness of Public Health practice. Italian Journal of Public Health 2006; 3: 29-33
  13. Leone MA, Avanzi GC, Lo Iacono A, Vigna-Taglianti F, Faggiano F. Gamma-hydroxybutyrate (GHB) for prevention and treatment of alcohol withdrawal. (Protocol) Cochrane Database of Systematic Reviews 2006, Issue 4. Art. No.: CD006266. DOI: 10.1002/14651858.CD006266. (IF 2007 4.654) (1°quint)
  14. Bargagli AM. Faggiano F. Amato L. Salamina G. Davoli M. Mathis F. Cuomo L. Schifano P. Burroni P. Perucci CA. For The VEdeTTE Study Group. VEdeTTE, a Longitudinal Study on Effectiveness of Treatments for Heroin Addiction in Italy: Study Protocol and Characteristics of Study Population. Substance Use & Misuse 2006 41:1861-79 (IF 2007: 1.229) (4°quint)
  15. Faggiano F, Vigna-Taglianti F, Bohrn K, Richardson C, Burkhart  G, Fabiani L, Lindahl AM, Melero JC, Panella M, Perez T, Siliquini R, Van Der Kreeft P, Wiborg G, Yotsidi V, Vasara M, Cuomo L. An effective school-based prevention programme for tobacco, alcohol, and drugs: the EU-Dap cluster randomized trial. European Journal of Public Health 2006; 16 (S1): 75-76. (IF 2007 1.910) (2°quint)
  16. Faggiano F, Vigna-Taglianti F. Quale valutazione per il sistema dei servizi per le tossicodipendenze? Bollettino per le Farmacodipendenze e l’Alcoolismo 2006. XXIX (3-4): 14-19.
  17. Faggiano F, Richardson C, Bohrn K, Galanti MR and the EU-Dap Study Group. A cluster randomized controlled trial of school-based prevention of tobacco, alcohol and drugs use: the EU-Dap design and study population. Preventive Medicine 2007; 44: 170–173. (IF 2007: 2.314) (2°quint)
  18. Galanti MR, Siliquini R, Cuomo L, Meleto JC, Perez T, Panella M, Faggiano F and the EU-DAP study group. Testing anonymous link procedures for follow-up of adolescents in a school-based trial: the EU-Dap pilot study. Preventive Medicine 2007; 44: 174–177. (IF 2007: 2.314) (2°quint)
  19. Vigna-Taglianti FD, Mathis F, Diecidue  R, Burroni P, Iannaccone A, Lampis F, Zuccaio P, Pacifici R, Versino E, Davoli M, Faggiano F. A follow-up study of heroin addicts (VEdeTTE2): study design and protocol. Substance Abuse Treatment, Prevention, and Policy 2007; 2:9 (15 Mar 2007). doi:10.1186/1747-597X-2-9
  20. Davoli M, Bargagli AM, Perucci CA, Schifano P, Belleudi V, Hickman M, Salamina G, Diecidue R, Vigna-Taglianti F & Faggiano F. Risk of fatal overdose during and after specialist drug treatment: the VEdeTTE study, a national multi-site prospective cohort study. Addiction 2007; 102: 1954–1959. (IF 2007: 4.014) (1°quint)
  21. Zambon A, Vigna-Taglianti F, Versino E, Borraccino A, Mathis F, Lemma P, Faggiano F. Gli interventi educativi in ambito scolastico nella prevenzione dell’uso di sostanze illecite: una revisione Cochrane per valutarne l’efficacia. Ed San & Prom alla Salute 2007; 30: 133-145
  22. Ferri M, Bargagli AM, Faggiano F, Belleudi V, Salamina G, Vigna-Taglianti F, Davoli M, Perucci CA, Gruppo Studio VEdeTTE*. Mortalità in una coorte di tossicodipendenti da eroina arruolati presso i Ser.T in Italia, 1998-2001. Epidemiologia & Prevenzione 2007; 31(5): 276-282.
  23. Faggiano F, Vigna-Taglianti F, Versino  E, Zambon A, Borraccino A, Lemma P. School-based prevention for illicit drugs use: A systematic review. Preventive Medicine 2008; 46: 385–396. (IF 2007: 2.314) (2°quint)
  24. Gontero P, Ceratti G, Guglielmetti S, Andorno A, Terrone C, Bonvini D, Faggiano F, Tizzani A, Frea B, Valente G. Prognostic factors in a prospective series of papillary renal cell carcinoma. British Journal of Urology 2008;102:697-702. (IF 2007 2.751) (2°quint)
  25. Clerico M, Faggiano F, Palace J, Rice G, Tintorè M, Durelli L. Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis. Cochrane Database Syst Rev 2008 Apr 16;(2):CD005278. Review. (IF 2007 4.654) (1°quint)
  26. Sogni F, Brausi M, Frea B, Martinengo C, Faggiano F, Tizzani A, Gontero P. Morbidity and quality of life in elderly patients receiving ileal conduit or orthotopic neobladder after radical cystectomy for invasive bladder cancer. Urology 2008;71:919-23. (IF 2007 2.134) (2°quint)
  27. Faggiano F, Galanti MR, Bohrn K, Burkhart G, Vigna-Taglianti F, Cuomo L, Fabiani L, Panella M, Perez T, Siliquini R, van der Kreeft P, Vassara M, Wiborg  G, and the EU-Dap Study Group. The effectiveness of a school-based substance abuse prevention program: EU-Dap Cluster Randomised Controlled Trial. Preventive Medicine 2008; 47: 537-543 (IF 2007: 2.314) (2°quint)
  28. Faggiano F. Sono utili le Linee Guida per la tabaccologia? Tabaccologia 2008; 3: 7-8
  29. Spadea T, D’errico A, Demaria M, Faggiano F, Pasian S, Zanetti R, Rosso S, Vicari P, Costa G. Educational inequalities in cancer incidence in Turin, Italy. Eur J Cancer Prev. 2009, 18(3):169-78.
  30. Faggiano F and on behalf of the EU-Dap Study Group. Response to “Hypothesis testing and the EU-Dap evaluation of the unplugged curriculum”. PM 2009; http://dx.doi.org/10.1016/j.ypmed.2009.04.005
  31. Vigna-Taglianti F, Vadrucci S, Faggiano F, Burkhart G, Siliquini R, Galanti MR, EU-Dap Study Group. Is universal prevention against youths' substance misuse really universal? Gender specific effects in the EU-Dap school-based prevention trial. J Epidemiol Community Health 2009;63:722–728
  32. van der Kreeft P, Wiborg G, Galanti MR, Siliquini R, Bohrn K, Scatigna M, Lindahl A-M, Melero JC, Vassara M, Faggiano F. ‘Unplugged’: A new European school programme against substance abuse. Drugs: Education, Prevention and Policy 2009; 16(2): 167–181
  33. van Lenthe FJ, de Bourdeaudhuij I, Klepp K-I, Lien N, Moore L, Faggiano F, Kunst AE, Mackenbach JP. Preventing socioeconomic inequalities in health behaviour in adolescents in Europe: Background, design and methods of project TEENAGE. BMC Public Health 2009, 9:125
  34. Barbieri A, Vanhaecht K, Van Herck P, Sermeus W, Faggiano F, Marchisio S, Panella M. Effects of clinical pathways in the joint replacement: a meta-analysis. BMC Med. 2009 Jul 1;7(1):32
  35. Faggiano F, Vigna-Taglianti F, Burkhart G, Bohrn K, Cuomo L, Gregori D, Panella M, Scatigna M, Siliquini R, Varona L, van der Kreeft P, Vassara M, Wiborg G, Galanti MR; the EU-Dap Study Group. The effectiveness of a school-based substance abuse prevention program: 18-Month follow-up of the EU-Dap cluster randomized controlled trial. Drug Alcohol Depend 2010;108:56-64
  36. Leone MA, Vigna-Taglianti F, Avanzi G, Brambilla R, Faggiano F. Gamma-hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses. Cochrane Database Syst Rev. 2010 Feb 17;2:CD006266.
  37. Salamina G, Diecidue R, Vigna-Taglianti F, Jarre P, Schefano P, Bargagli AM, Davoli M, Amato L, Perucci CA, Faggiano F and the VEdeTTE Study Group. Effectiveness of Therapies for Heroin Addiction in Retaining Patients in Treatment: Results From the VEdeTTE Study. Substance Use & Misuse 2010;45: 2076-92
  38. Faggiano F. Prevention of substance abuse: randomised or observational evaluation is absolutely needed. Adicciones. 2010;22(1):11-4.
  39. Davoli M, Faggiano F. The contribution of the Italian Epidemiology to the European research on drugs and alcohol. Epidemiol Prev. 2010 Sep-Dec;34(5-6):35-38.
  40. Amato L, Davoli M, Vecchi S, Ali R, Farrell M, Faggiano F, Foxcroft D, Ling W, Minozzi S, Chengzheng Z. Cochrane systematic reviews in the field of addiction: What's there and what should be. Drug Alcohol Depend 2011; 113: 96-103
  41. Caria MP, Faggiano F, Bellocco R, Galanti MR; EU-Dap Study Group. Effects of a school-based prevention program on European adolescents' patterns of alcohol use. J Adolesc Health. 2011 Feb;48(2):182-8.
  42. De Bourdeaudhuij I, Simon C, De Meester F, Van Lenthe F, Spittaels H, Lien N, Faggiano F, Mercken L, Moore L, Haerens L. Are physical activity interventions equally effective in adolescents of low and high socio-economic status (SES): results from the European Teenage project. Health Educ Res. 2011 Feb;26(1):119-30.
  43. Brown CH, Sloboda Z, Faggiano F, Teasdale B, Keller F, Burkhart G, Vigna-Taglianti F, Howe G, Masyn K, Wang W, Muthén B, Stephens P, Grey S, Perrino T; Prevention Science and Methodology Group. Methods for Synthesizing Findings on Moderation Effects Across Multiple Randomized Trials. Prev Sci. 2011 Mar 1. [Epub ahead of print]
  44. Faggiano F. Reaction to the article: Environmental drug prevention in the EU - why is it so unpopular? by Gregor Burkhart. Adicciones 2011; 23: 101-102
  45. Morgenstern M, Poelen EAP, Scholte R, Karlsdottir S, Jonsson SH, Mathis F, Faggiano F, Florek E, Sweeting H, Hunt K, Sargent JD, Hanewinkel R. Smoking in movies and adolescent smoking: cross-cultural study in six European countries. Thorax 2011, ahead of printing
  46. Caria MP, Faggiano F, Bellocco R, Galanti MR. The influence of socioeconomic environment on the effectiveness of alcohol prevention among European students: a cluster randomized controlled trial. BMC Public Health. 2011 May 13;11:312.
  47. High youth access to movies that contain smoking in Europe compared with the USA. Hanewinkel R, Sargent JD, Karlsdottir S, Hrafn Jonsson S, Mathis F, Faggiano F, Poelen EAP, Scholte R, Florek E, Sweeting E, Hunt K, Morgenstern M. Tobacco Control 2011. Ahead of printing. 10.1136/tobaccocontrol-2011-050050